For the quarter ended June 2025, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $240.68 million, up 8.5% over the same period last year. EPS came in at -$0.48, compared to -$0.47 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $238.61 million, representing a surprise of +0.87%. The company delivered an EPS surprise of -20%, with the consensus EPS estimate being -$0.40.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Pump Shipments - Total Worldwide: 30,000 compared to the 30,679 average estimate based on two analysts.
- Pump Shipments - Outside the United States: 9,000 versus 9,093 estimated by two analysts on average.
- Pump Shipments - United States: 21,000 versus 21,586 estimated by two analysts on average.
- Sales- Pump- United States: $85.47 million versus $91.75 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.
- Geographic Sales- Outside the United States: $70.47 million compared to the $65.57 million average estimate based on four analysts. The reported number represents a change of +8.1% year over year.
- Sales- Supplies and Other- Outside the United States: $44.07 million versus the four-analyst average estimate of $41.64 million. The reported number represents a year-over-year change of +12.8%.
- Sales- Pump- Outside the United States: $26.4 million compared to the $23.93 million average estimate based on four analysts. The reported number represents a change of +1.1% year over year.
- Sales- Supplies and Other- United States: $84.74 million versus $80.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.3% change.
- Geographic Sales- United States: $170.21 million versus the three-analyst average estimate of $173.34 million. The reported number represents a year-over-year change of +8.6%.
- Revenue- Supplies and Other: $128.81 million compared to the $122.4 million average estimate based on five analysts.
- Revenue- Pump: $111.87 million versus the five-analyst average estimate of $115.69 million.
View all Key Company Metrics for Tandem Diabetes Care here>>>
Shares of Tandem Diabetes Care have returned -8.8% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
